Composition for the prevention and treatment of skin hyperpigmentation based on niacinamide or one of its derivatives and a Cystoseira algae extract

Abstract

The present invention relates to a composition for the prevention and / or treatment of hyperpigmentation of the skin and / or hair, comprising the combination of niacinamide or one of its derivatives with an extract of algae of the genus Cystoseira. The invention also relates to the cosmetic and dermatological uses of the composition according to the invention, as well as a method for preventing and / or treating hyperpigmentation of the skin and / or hair.

Description

Title of the invention: COMPOSITION FOR THE PREVENTION AND TREATMENT OF HYPERPIGMENTATION OF SKIN BASED ON NIACINAMIDE OR ONE OF ITS DERIVATIVES AND AN EXTRACT OF CYSTOSEIRA ALGAE

[0001] The present invention relates to a composition for the prevention and / or treatment of the appearance of hyperpigmentation of the skin and / or hair, comprising the combination of niacinamide or one of its derivatives with an extract of algae of the genus Cystoseira.

[0002] The invention also relates to the cosmetic and dermatological uses of the composition according to the invention, as well as a method for preventing and / or treating the appearance of hyperpigmentation of the skin and / or hair.

[0003] Prized in Asian countries where fair skin is a true aesthetic criterion, but also by Western populations where an even complexion is a sign of good health, skin-lightening products have become a genuine social phenomenon. The dermatology and cosmetics sectors have responded to this need by offering depigmenting, lightening, or whitening products designed to promote the elimination of pigment spots (sun spots, freckles, age spots, post-inflammatory hyperpigmentation) or to brighten the complexion.

[0004] Skin and hair follicle pigmentation results from the exposure of melanin to the surface of the skin and hair follicle. Melanogenesis is specifically carried out by melanocytes, dendritic cells present in the basal layer of the epidermis, which extend branches that contact keratinocytes. The newly synthesized melanin is transferred from the melanocyte dendrites to the keratinocytes, which ultimately expose the melanin to the surface of the epidermis, thus ensuring uniform pigmentation of the epidermis.

[0005] The synthesis of melanins (pheomelanins, rich in sulfur, giving an orange color; eumelanins, giving a brown color) is carried out within melanosomes, organelles related to lysosomes specific to melanocytes, by a complex enzymatic process. Three enzymes located on the inner surface of the melanosomal membrane are successively involved in melanogenesis: tyrosinase, TRP-2 (tyrosinase-related protein-2), and TRP-1 (tyrosinase-related protein-1). Tyrosine, a precursor of melanin synthesis, is hydroxylated to DOPA (dihydroxyphenylalanine) and then oxidized to dopaquinone; both transformations are due to the action of tyrosinase.

[0006] At this stage, melanin synthesis can be directed towards pheomelanin (yellow-orange melanin) found in blond or red-haired individuals, or towards eumelanin (dark brown melanin) found in individuals with dark pigmentation. Eumelanin results from the polymerization of dopaquinone to leucodopachrome and then to dopachrome. The latter is in turn converted either into 5,6-dihydroxyindole (DHI) or 5,6-dihydroxyindole-2-carboxylic acid (DHICA) under the action of TRP-2. At this point, eumelanin synthesis can occur via two pathways. DHI is oxidized by tyrosinase or a peroxidase to indole 5,6-quinone, while DHICA, by TRP-1, leads to 5,6-dihydroindole-2-carboxy acid. Indole 5,6-quinone and 5,6-dihydroindole-2-carboxy acid polymerize to form melanochromes and then eumelanin.

[0007] Pheomelanin synthesis involves the formation of sulfur compounds (cysteinyl-DOPA) following the action of glutathione and cysteine ​​on dopaquinone. Cysteinyl-DOPA is transformed into alanyl-hydroxybenzothiazine, and then into pheomelanin.

[0008] The molecular mechanisms regulating melanocytes and melanin production are relatively poorly understood. The work of Y. Yada showed that under the influence of UVB solar radiation, human keratinocytes produce and secrete the peptide hormone endothelin, which exerts a paracrine effect on melanocytes (Imokawa G et al, J. Invest. Dermatol., 105:32-37, 1995). Endothelin activates a membrane receptor (ETR) coupled to a G protein, inducing melanocyte proliferation and the transcription of genes encoding tyrosinase and ETR. Similarly, in response to UV radiation, keratinocytes and melanocytes secrete the peptide aMSH (melanocortin-stimulating hormone), which regulates melanocyte pigmentation activity.To achieve this, aMSH binds to the MC-R (melanocortin receptor), inducing activation of the cAMP / PKA signaling pathway and potentially the ser / thr kinase PKC, leading to de novo tyrosinase synthesis and eumelanin synthesis. PKC[3] directly activates tyrosinase by phosphorylation of its cytoplasmic domain (Park et al., J. Biol. Chem., 268: 11742-11749, 1993). aMSH also facilitates melanin transfer to keratinocytes by stimulating melanocyte dendriticization (Hunt et al., J. Cell. Sci., 107: 205-211, 1994).

[0009] In addition to the desire of some individuals or populations to obtain and maintain a fair complexion, the problem of preventing and treating localized hyperpigmentation, in the form of spots, also arises for many. Localized hyperpigmentation of the skin can be of endogenous origin, as is the case with freckles, which are common in people with fair skin. It can also be the result of UV exposure. An increase in freckles, whose color darkens, is observed under the effect of UV radiation. It is also noted The appearance of hyperpigmented patches in areas subject to irritation (insect bites, slow-healing wounds, eczema, etc.) • Hormonal factors are responsible for regional hyperpigmentation due to melanocyte hyperactivity, such as idiopathic melasma occurring during pregnancy (mask of pregnancy) or with estrogen-progestin contraception. Similarly, pigment spots due to benign melanocyte hyperactivity and proliferation (senile lentigines) often appear in the elderly.

[0010] Substances known for their depigmenting properties may act according to one of the following mechanisms: - on the viability of epidermal and / or follicular melanocytes where melanogenesis takes place, - by interfering with one of the steps in melanin biosynthesis, or by inhibiting one of the enzymes involved in melanogenesis, or by interposing itself as a structural analog of one of the chemical compounds in the melanin synthesis pathway, - by interfering with the transfer of melanin from melanocytes to keratinocytes.

[0011] The most commonly used substances are mostly tyrosinase inhibitors. Phenolic derivatives are an example. These derivatives have a chemical structure comparable to that of tyrosine or dopa and serve as substrates for tyrosinase (competitive inhibition). Hydroquinone and its derivatives belong to this family. However, these products exhibit significant cytotoxicity, which can cause irreversible depigmentation, and the use of hydroquinone in cosmetic products has been prohibited by European regulation (Dir. 2000 / 6BC).

[0012] Various other substances are proposed as depigmenting agents. Some have good local tolerance but also reduced efficacy: vitamin C, arbutin (hydroquinone [3-D-gluconopyranoside], niacinamide, which acts on the transfer of melanosomes from melanocytes to keratinocytes (Hakozaki T. et al., British Journal of Dermatology, 147: 20-31, 2002), soy extracts (Paine C. et al., Journal of Investigative Dermatology, 116, 4: 587-595 2001,) which inhibit the activity of the PAR-2 ​​(protease-activated receptor 2) receptor expressed by keratinocytes.

[0013] There is therefore a real need to develop non-toxic compositions capable of preventing and / or treating the appearance of hyperpigmentation of the skin and / or hair, whether it is hyperpigmentation of endogenous or exogenous origin (UV, skin irritation, hormonal), and whose action is reversible.

[0014] In addition, the compositions must demonstrate good efficacy in preventing or treating regional hyperpigmentation due to melanocyte hyperactivity, such as: - idiopathic melasma, occurring during pregnancy, also called pregnancy mask or chloasma, or those which are the consequence of estrogen-progestin contraception; - localized hyperpigmentations due to hyperactivity and benign melanocytic proliferation, such as freckles, sun spots or senile pigment spots, known as actinic lentigines; - Accidental hyperpigmentation or depigmentation, possibly due to photosensitization or post-lesional scarring, such as in areas subjected to irritation (insect bite, slow-healing wound, eczema, etc.), as well as certain leukodermas such as vitiligo.

[0015] Finally, it is also of interest that the compositions be able to whiten the skin and / or lighten the complexion, and / or even out the complexion.

[0016] These objectives are achieved with the present invention, which relates in particular to a composition, preferably cosmetic and / or dermatological, comprising: i. at least one first active ingredient selected from niacinamide, risoniacinamide, methyl niacinamide chloride, niacinamide salts, isoniacinamide salts, and mixtures thereof; and ii. at least one second active ingredient chosen from extracts of algae of the genus Cystoseira, the total content of which is in the range of 0.001 to 2% by weight, relative to the total weight of the composition.

[0017] It has been found surprisingly that the composition according to the invention makes it possible to prevent and treat effectively the appearance of hyperpigmentation of the skin and / or hair, whether it is hyperpigmentation of endogenous or exogenous origin (UV, skin irritation, hormonal).

[0018] The composition according to the invention is particularly effective for the prevention and / or treatment of regional hyperpigmentations due to melanocyte hyperactivity.

[0019] It has been observed that the effectiveness of the composition according to the invention persists for several days after stopping application to the skin, in particular even after 14 days of stopping.

[0020] Furthermore, the composition according to the invention does not exhibit toxicity and its action is reversible.

[0021] It has also been found that the composition according to the invention is capable of whitening the skin, brightening the complexion, and evening out the complexion, in a significant way.

[0022] In a particularly surprising way, the Applicant discovered that the combination of niacinamide with an extract of Cystoseira Tamariscifolia makes it possible to obtain significantly improved results in terms of prevention and treatment of the appearance of hyperpigmentation of the skin and / or hair, as well as skin whitening, brightening of the complexion, and unifying of the complexion.

[0023] The invention also relates to the use of the composition according to the invention, to prevent and / or treat the appearance of hyperpigmentation of the skin and / or hair.

[0024] The invention also relates to the use of the composition according to the invention, to whiten the skin and / or lighten the complexion, and / or even out the complexion.

[0025] Furthermore, the invention relates to a method for preventing and / or treating the appearance of hyperpigmentation of the skin and / or hair, comprising at least one step of applying an effective amount of the composition according to the invention.

[0026] Other objects, features, aspects and advantages of the invention will become even clearer upon reading the description and example that follows.

[0027] In this description, and unless otherwise indicated: - the expression "at least one" is equivalent to the expression "one or more" and can be substituted for it; - the expression "between... and..." is equivalent to the expression "ranging from... to..." and can be substituted for it, and implies that the limits are included; - By the expression "greater than" and respectively the expression "less than" in the meaning of the present invention, we mean an open interval that is strictly greater than, respectively strictly less than, and therefore that the bounds are not included. - The term "extract" refers to a product obtained by extracting certain compounds from an animal or vegetable substance. An extract can be obtained by methods well known to those skilled in the art. These methods include the use of an extraction solvent, the extraction solvent being in liquid or gaseous form, used at ambient temperature or heated, used at ambient pressure or under positive pressure, used with or without enzymes, and used with or without bases or acids. The first asset

[0028] The composition according to the invention comprises at least one first active ingredient selected from niacinamide, isoniacinamide, methyl-niacinamide chloride, niacinamide salts and isoniacinamide salts.

[0029] Preferably, the first active ingredient(s) are chosen from niacinamide, isoniacinamide, methyl niacinamide chloride, niacinamide ascorbate, niacinamide glycolate, niacinamide hydroxybenzoate, hydroxycitrate niacinamide, niacinamide lactate, niacinamide malate, niacinamide mandelate, niacinamide salicylate, niacinamide thioctate, and mixtures thereof;

[0030] More preferably, the first active ingredient(s) are chosen from niacinamide, niacinamide ascorbate, niacinamide glycolate, niacinamide hydroxybenzoate, niacinamide hydroxycitrate, niacinamide lactate, niacinamide malate, niacinamide mandelate, niacinamide salicylate, niacinamide thioctate, and mixtures thereof.

[0031] In a particularly preferred manner, the first active ingredient is niacinamide.

[0032] Niacinamide has the following chemical structure:

[0033] Niacinamide is also known by the names: nicotinamide and 3-pyridinecarboxamide.

[0034] Preferably, the total content of first active ingredient(s) is in the range of 0.1 to 10% by weight; more preferably 0.5 to 7% by weight; more preferably still 1 to 5% by weight; and even better 2 to 4% by weight, relative to the total weight of the composition.

[0035] Preferably, the total niacinamide content is in the range of 0.1 to 10% by weight; more preferably 0.5 to 7% by weight; more preferably still 1 to 5% by weight; and even better 2 to 4% by weight, relative to the total weight of the composition. The second asset

[0036] The composition according to the invention comprises at least one second active ingredient selected from extracts of algae of the genus Cystoseira, the total content of which is in the range of 0.001 to 2% by weight, relative to the total weight of the composition.

[0037] The classification of Cystoseira algae is broken down as follows: Reign: Chromista Phylum: Ochrophyta Class: Phaeophyceae Subclass: Fucophycidae Order: Fucales Family: Sargassacea Genus: Cystoseira

[0038] Preferably, the second active ingredient(s) are chosen from Cystoseira Amentacea extract, Cystoseira Caespitosa extract, Cystoseira Branchycarpa extract, Cystoseira Baccata extract, Cystoseira Balearica extract, Cystoseira Compressa extract, Cystoseira Humilis extract, Cystoseira Tamariscifolia extract, and mixtures thereof.

[0039] These extracts are marketed for example under the names Sea Heather® (from Gelyma), cystoseira tamaricifolia oil® (from Codif Int.) and Seamoist-CH® (from Naturalis Sri).

[0040] In a particularly preferred manner, the second active ingredient is an extract of Cystoseira Tamariscifolia.

[0041] Preferably, the total content of second active ingredient(s) is in the range of 0.001 to 1% by weight; more preferably 0.005 to 0.5% by weight; more preferably still 0.005 to 0.1% by weight; better 0.01 to 0.05% by weight, and even better 0.01 to 0.02% by weight, relative to the total weight of the composition.

[0042] Preferably, the total content of Cystoseira Tamariscifolia extract is in the range of 0.001 to 1% by weight; more preferably 0.005 to 0.5% by weight; more preferably still 0.005 to 0.1% by weight; better 0.01 to 0.05% by weight, and even better 0.01 to 0.02% by weight, relative to the total weight of the composition.

[0043] Preferably, the weight ratio of the total content of first active ingredient(s) to the total content of second active ingredient(s) in the composition according to the invention is greater than or equal to 1; more preferably greater than 1; more preferably still between 5 and 1,000; better between 10 and 800; better between 50 and 500; even better still between 100 and 450; still better between 120 and 400; or even between 130 and 270.

[0044] Preferably, the weight ratio of the total content of niacinamide to the total content of Cystoseira Tamariscifolia extract in the composition according to the invention is greater than or equal to 1; more preferably greater than 1; more preferably still between 5 and 1,000; better between 10 and 800; better between 50 and 500; even better still between 100 and 450; still better between 120 and 400; or even between 130 and 270.

[0045] Polyols Preferably, the composition according to the present invention further comprises one or more C2-C8 polyols.

[0046] For the purposes of this invention, "C2-C8 polyol" means an organic compound consisting of a C2-C8 hydrocarbon chain, optionally interrupted by one or more oxygen atoms, and bearing at least two free hydroxyl groups (-OH) on different carbon atoms. which can be cyclic or acyclic, linear or branched, saturated or unsaturated, and in liquid state at room temperature (25°C) and atmospheric pressure (i.e. 1.013.105 Pa).

[0047] Preferably, the C2-C8 polyol(s) according to the invention are acyclic and non-aromatic.

[0048] The C2-C8 polyols according to the invention comprise in their structure 2 to 8 carbon atoms, preferably 2 to 6 carbon atoms, more preferably 2 to 5 carbon atoms.

[0049] More particularly, the polyol(s) usable according to the invention comprise from 2 to 10 hydroxy groups, more preferably from 2 to 5 hydroxy groups, more preferably still from 2 to 3 hydroxy groups.

[0050] Preferably, the C2-C8 polyol(s) usable according to the invention are chosen from C3-C6 polyols, ethylene glycol, and mixtures thereof.

[0051] According to a preferred embodiment of the invention, the C2-C8 polyol(s) usable according to the invention are selected from propylene glycol, 1,3-propanediol, 1,3-butylene glycol, pentane-1,2-diol, dipropylene glycol, hexylene glycol, pentylene glycol, glycerol, ethylene glycol, and mixtures thereof; more preferably the composition includes at least glycerol.

[0052] Preferably, the total content of C2-C8 polyol(s) is between 1 and 25% by weight, more preferably between 2 and 20% by weight, more preferably between 5 and 15% by weight, and better between 5 and 12% by weight, relative to the total weight of the composition.

[0053] Preferably, the total glycerol content is between 1 and 25% by weight, more preferably between 2 and 20% by weight, more preferably between 5 and 15% by weight, and better between 5 and 12% by weight, relative to the total weight of the composition. The beneficial agents

[0054] Preferably, the composition according to the present invention further comprises one or more beneficial agents selected from gluconolactone, acetyl glucosamine, lauroyl lysine, octadecenedioic acid and its salts, Bacillus ferments (INCI name: Bacillus ferment), bisabolol, 3-o-ethyl-ascorbic acid and its salts, citric acid and its salts, Schisandra sphenanthera fruit extract (INCI name: Schisandra Sphenanthera Fruit Extract), and mixtures thereof.

[0055] In particular, it has been discovered in a surprising way that these beneficial agents potentiate the action of the combination of niacinamide or one of its derivatives with an extract of algae of the genus Cystoseira, in terms of the prevention and treatment of the appearance of hyperpigmentation of the skin and / or hair, as well as skin whitening, brightening of the complexion, and unifying of the complexion.

[0056] In particular, the composition according to the present invention further comprises one or more beneficial agents selected from gluconolactone, acetyl glucosamine, lauroyl lysine, Bacillus ferments (INCI name: Bacillus ferment), bisabolol, citric acid and its salts, Schisandra sphenanthera fruit extract (INCI name: Schisandra Sphenanthera Fruit Extract), and mixtures thereof.

[0057] More preferably, the composition according to the present invention further comprises one or more beneficial agents selected from gluconolactone, acetyl glucosamine, an extract of Schisandra sphenanthera fruit, and mixtures thereof; more preferably still gluconolactone, acetyl glucosamine, and mixtures thereof.

[0058] And more preferably, the composition according to the invention comprises gluconolactone.

[0059] Preferably, the total content of beneficial agent(s) is between 0.01 and 25% by weight, more preferably between 0.1 and 20% by weight, more preferably between 1 and 20% by weight, better between 5 and 15% by weight, relative to the total weight of the composition.

[0060] Preferably, the total gluconolactone content is between 0.1 and 15% by weight, more preferably between 1 and 10% by weight, more preferably between 5 and 10% by weight, relative to the total weight of the composition.

[0061] Preferably, the total acetyl glucosamine content is between 0.01 and 10% by weight, more preferably between 0.05 and 5% by weight, more preferably still between 0.1 and 2% by weight, and better between 0.5 and 1% by weight, relative to the total weight of the composition.

[0062] According to a preferred embodiment of the invention, the composition further comprises an extract of Schisandra sphenanthera fruit.

[0063] According to this preferred embodiment, the total content of Schisandra sphenanthera fruit extract in the composition is between 0.001 and 2% by weight, more preferably between 0.01 and 1% by weight, more preferably still between 0.02 and 0.5% by weight, and even better between 0.05 and 0.25% by weight, relative to the total weight of the composition. Surfactants

[0064] Preferably, the composition according to the present invention further comprises one or more surfactants.

[0065] The surfactants that can be used according to the invention can be chosen from anionic surfactants, cationic surfactants, amphoteric and / or zwitterionic surfactants, non-ionic surfactants, and mixtures thereof.

[0066] More preferably, the surfactant(s) are chosen from anionic surfactants, non-ionic surfactants, and mixtures thereof.

[0067] The non-ionic surfactants usable according to the invention can be chosen from alkyl polyglucosides (APGs), oxyalkylated glycerol esters, oxyalkylated fatty acid and sorbitan esters, polyoxyalkylated fatty acid esters (in particular polyoxyethylenated and / or polyoxypropylenated) possibly in association with a fatty acid and glycerol ester such as the PEG-100 Stearate / Glyceryl Stearate mixture, oxyalkylated sugar esters, and mixtures thereof.

[0068] Examples of alkyl polyglucosides include those containing an alkyl group with 6 to 30 carbon atoms, and preferably 8 to 16 carbon atoms, and a glucoside group preferably comprising 1.2 to 3 glucoside units. For example, alkyl polyglucosides may be selected from decyl glucoside (Alkyl-C9 / Cn-poly glucoside (1,4)), such as the product marketed under the name Plantacare 2000 UP® by Cognis; caprylyl / capryl glucoside, such as the product marketed under the name Plantacare KE 3711® by Cognis; lauryl glucoside, such as the product marketed under the name Plantacare 1200 UP® by Cognis; and coco glucoside, such as the product marketed under the name Plantacare 818 UP® by Cognis. caprylylglucoside such as the product marketed under the name Plantacare 810 UP® by the company Cognis; and their mixtures.

[0069] Preferably, the number of moles of alkylene oxide of the non-ionic surfactants usable according to the invention varies from 2 to 400; more preferably from 4 to 250.

[0070] According to a particular embodiment of the invention, the composition further comprises at least one non-ionic surfactant; more preferably a non-ionic surfactant selected from the (C6-C30)alkylpolyglucosides; more preferably still at least one non-ionic surfactant selected from decylglucoside, caprylyl / capryl glucoside, laurylglucoside, cocoglucoside, caprylylglucoside and mixtures thereof.

[0071] The anionic surfactants usable according to the invention can be chosen from among the sulfonate anionic surfactants such as the following compounds: alkylsulfonates, alkylamidesulfonates, alkylarylsulfonates, alkylsulfosuccinates, alkylethersulfosuccinates, alkylamidesulfosuccinates, alkylsulfoacetates; as well as the salts of these compounds; the alkyl groups of these compounds comprising from 6 to 30 carbon atoms, in particular from 10 to 28, even better from 12 to 24, or even from 14 to 20, carbon atoms; the aryl group preferably designating a phenyl or benzyl group; these compounds being able to be polyoxyalkylated, in particular polyoxyethylated and then preferably comprising from 1 to 50 ethylene oxide motifs, better from 2 to 10 ethylene oxide motifs.

[0072] According to another particular embodiment of the invention, the composition further comprises at least one anionic surfactant; more preferably a anionic surfactant chosen from among the C6-C24 alkylsulfosuccinates, especially in Ci2-C2o, and even more preferably cetearyl sulfosuccinates, and its salts.

[0073] Preferably, the total surfactant content is between 0.1 and 20% by weight, more preferably between 0.5 and 15% by weight, more preferably between 0.5 and 4% by weight, relative to the total weight of the composition.

[0074] Preferably, the total content of non-ionic surfactant(s) is between 0.1 and 20% by weight, more preferably between 0.5 and 15% by weight, more preferably between 0.5 and 4% by weight, relative to the total weight of the composition.

[0075] Preferably, the total content of (C6-C30)alkylpolyglucoside(s) is between 0.1 and 20% by weight, more preferably between 0.5 and 15% by weight, more preferably between 0.5 and 4% by weight, relative to the total weight of the composition.

[0076] Preferably, the total content of anionic surfactant(s) is between 0.01 and 10% by weight, more preferably between 0.05 and 5% by weight, more preferably still between 0.1 and 3% by weight, and even better between 0.5 and 2% by weight, relative to the total weight of the composition.

[0077] Preferably, the total content of C6-C24 alkylsulfosuccinate(s) is between 0.01 and 10% by weight, more preferably between 0.05 and 5% by weight, more preferably still between 0.1 and 3% by weight, and even better between 0.5 and 2% by weight, relative to the total weight of the composition.

[0078] Preferably, the composition according to the invention further comprises one or more UV filters, in particular one or more UV-A and / or UV-B filters.

[0079] The UV filters usable according to the invention can be organic such as benzoxazole compounds, p-aminobenzoic (PABA), bis-benzoazolyls, imidazolines, benzimidazoles, benzotriazoles, triazines, benzophenones, salicylates, dibenzoylmethanes and cinnamics; or inorganic such as metal oxides (titanium oxide, zinc oxide, etc.) coated or uncoated.

[0080] Preferably, the total UV filter content is between 0.1 and 40% by weight, more preferably between 1 and 35% by weight, more preferably still between 5 and 30% by weight, and even better between 10 and 25% by weight, or even between 15 and 25% by weight, relative to the total weight of the composition.

[0081] Preferably, the composition according to the invention is free of silicone.

[0082] By the expression "silicone-free", it is understood that the composition according to the invention does not comprise silicone, or that the silicone(s) present in the composition according to the invention are comprised in a total content of less than or equal to 0.1% by weight, preferably less than or equal to 0.05% by weight, plus preferably less than or equal to 0.01% by weight, relative to the total weight of the composition according to the invention, better free of silicone (0% by weight).

[0083] By "silicone" is meant any organosilicon polymer or oligomer with a linear or cyclic, branched or cross-linked structure, of variable molecular weight, obtained for example by polymerization and / or by polycondensation of suitably functionalized silanes, and consisting essentially of a repetition of principal motifs in which the silicon atoms are linked together by oxygen atoms (siloxane bond -Si-O-Si-), with hydrocarbon radicals possibly substituted being directly linked via a carbon atom to said silicon atoms; and more particularly dialkylsiloxane polymers, amino silicones, dimethiconols.

[0084] Preferably, the composition according to the invention comprises water, i.e. the medium of the composition is aqueous or hydroalcoholic.

[0085] More preferably, the total water content of the composition according to the invention is between 20 and 98% by weight, more preferably between 25% and 80% by weight, more preferably still between 30 and 70% by weight, even better between 35 and 65% by weight, relative to the total weight of the composition.

[0086] The composition according to the invention may advantageously further comprise at least one organic solvent, different from the polyols described above.

[0087] For the purposes of the invention, it is understood that the organic solvents are liquid at 25°C and at atmospheric pressure.

[0088] Examples of organic solvents, other than the polyols described above, include aliphatic or aromatic monoalcohols in the C2-C8 range, and C3-C8 polyol ethers, which can be used alone or in mixtures with water. Advantageously, the organic solvent(s) can be chosen from ethanol, isopropanol, and mixtures thereof.

[0089] The composition according to the invention may optionally also contain one or more additives used in cosmetics and dermatology, such as perfumes, thickeners, fats, colorants, pH buffers, antioxidants, antibacterials and / or antifungals.

[0090] These additives may be present in the composition according to the invention in an amount ranging from 0 to 35% by weight relative to the total weight of the composition.

[0091] A person skilled in the art will take care to choose these possible additives and their quantities so that they do not impair the properties of the compositions of the present invention.

[0092] The compositions according to the invention can be presented in all the pharmaceutical forms usually used for topical application (and preferably for cutaneous application), and in particular in the form of an aqueous solution, These formulations can be hydroalcoholic or oil-based. They may be in the form of a water-in-oil emulsion, an oil-in-water emulsion, a multiple emulsion, a dispersion of nanoparticles or lipid vesicles such as liposomes, an aqueous gel, an oily gel, or an anhydrous liquid, paste, or solid product. This cosmetic and / or dermatological composition may consist of a formula such as: lotion, gel, cream, mousse, ointment, patch, mask, stick, shampoo, conditioner, or makeup product.

[0093] Preferably, the composition according to the invention is an emulsion, and more preferably an oil-in-water emulsion.

[0094] The composition according to the invention is preferably a cosmetic and / or dermatological composition, and advantageously comprises a cosmetically acceptable or dermatologically acceptable medium.

[0095] The composition according to the invention is preferably topical, and more preferably intended to be applied to the skin and / or hair, and in particular to the face such as the eye contour, and to the body in particular the legs, back, neck, arms, décolleté / bust, feet and hands.

[0096] The composition according to the invention is more particularly intended to be applied to friction areas such as elbows, armpits, groin, knees; and to external mucous membranes such as external genital mucous membranes.

[0097] According to a preferred embodiment of the invention, the composition comprises: i. at least one first active ingredient selected from niacinamide, isoniacinamide, methylniacinamide chloride, niacinamide salts, isoniacinamide salts, and mixtures thereof, the total content of which is in the range of 0.1 to 10% by weight, relative to the total weight of the composition; and ii. at least one second active ingredient selected from extracts of algae of the genus Cystoseira, the total content of which is in the range of 0.001 to 2% by weight, relative to the total weight of the composition; and

[0098] the weight ratio of the total content of first active ingredient(s) to the total content of second active ingredient(s) is greater than or equal to 1; preferably greater than 1; more preferably between 5 and 1,000; more preferably still between 10 and 800; better between 50 and 500; better still between 100 and 450; or even between 120 and 400; or even between 130 and 270.

[0099] According to another preferred embodiment of the invention, the composition comprises: i. niacinamide, the total content of which is within the range ranging from 0.1 to 10% by weight, preferably from 0.5 to 7% by weight, more preferably from 1 to 5% by weight, and even more preferably from 2 to 4% by weight, relative to the total weight of the composition; and ii. an extract of Cystoseira Tamariscifolia, the total content of which is in the range of 0.001 to 2% by weight, preferably 0.005 to 0.5% by weight, more preferably 0.005 to 0.1% by weight, more preferably 0.01 to 0.05% by weight, better 0.01 to 0.02% by weight, relative to the total weight of the composition; and

[0100] possibly with a weight ratio of the total niacinamide content to the total Cystoseira Tamariscifolia extract content greater than or equal to 1; more preferably greater than 1; more preferably between 5 and 1,000; better between 10 and 800; better between 50 and 500; even better between 100 and 450; always better between 120 and 400; or even between 130 and 270.

[0101] According to yet another preferred embodiment of the invention, the composition comprises: i. niacinamide, the total content of which is in the range of 0.1 to 10% by weight, preferably 0.5 to 7% by weight, more preferably 1 to 5% by weight, more preferably 2 to 4% by weight, relative to the total weight of the composition; ii. an extract of Cystoseira Tamariscifolia, the total content of which is in the range of 0.001 to 2% by weight, preferably 0.005 to 0.5% by weight, more preferably 0.005 to 0.1% by weight, more preferably 0.01 to 0.05% by weight, better 0.01 to 0.02% by weight, relative to the total weight of the composition; iii. one or more C2-C8 polyols, preferably glycerol; and iv. optionally one or more beneficial agents selected from gluconolactone, acetyl glucosamine, lauroyl lysine, octadecenedioic acid and its salts, Bacillus ferments (INCI name: Bacillus ferment), bisabolol, 3-o-ethyl-ascorbic acid and its salts, citric acid and its salts, Schisandra sphenanthera fruit extract (INCI name: Schisandra Sphenanthera Fruit Extract), and mixtures thereof; preferably from gluconolactone, acetyl glucosamine, Schisandra sphenanthera fruit extract, and mixtures thereof; more preferably gluconolactone, acetyl glucosamine, and mixtures thereof; and more preferably gluconolactone.

[0102] The invention also relates to the use of the composition as described above, to prevent and / or treat the appearance of hyperpigmentation of the skin and / or hair.

[0103] The invention also relates to the composition as described above, for its use in the prevention and / or treatment of the appearance of hyperpigmentation of the skin and / or hair.

[0104] The invention also relates to the use of the composition as described above, to whiten the skin and / or lighten the complexion, and / or even out the complexion.

[0105] The invention also relates to the composition as described above, for its use in whitening the skin and / or lightening the complexion, and / or evening out the complexion.

[0106] Furthermore, the invention relates to a method for preventing and / or treating the appearance of hyperpigmentation of the skin and / or hair, comprising at least one step of applying an effective amount of the composition as described above, to the skin and / or hair, and preferably to the face such as the eye contour, and to the body in particular the legs, back, neck, arms, décolleté / bust, feet and hands.

[0107] In addition, the composition can more particularly be applied to areas of friction such as elbows, armpits, groin, knees; and to external mucous membranes such as external genital mucous membranes.

[0108] Preferably, said effective amount applied is between 0.5 and 1000mg of composition / kg of user / day; more preferably between 1 and 800mg / kg / day; and more preferably still between 2 and 500mg / kg / day.

[0109] Advantageously, the application step of the process according to the invention is carried out at least once a week; more preferably twice a week, more preferably still at least once a day, or even at least twice a day.

[0110] The following examples serve to illustrate the invention without, however, being limiting in nature. Examples [YES] Example 1: Compositions Al, A2, A3, A4 and A5 according to the invention are prepared from the ingredients indicated (INCI names) in the tables below, the quantities of which are expressed as % by weight of active substance (AS).

[0112] [Tables 1] Ingredients Al Niacinamide 2 Cystoseira Tamariscifolia extract 0.015 Glycerol 7.75 Gluconolactone 7 Lauroyl Lysine 4 Decyl Glucoside 5.3 Sodium Carboxymethyl Starch 11 Coco-betaine 1.55 Propanediol 4 Xanthan gum 0.2 Bambusa Arundinacea Stem Powder 0.75 Preservatives Qs Water Qsp 100

[0113] [Tables2] Ingredients A2 Niacinamide 4 Cystoseira Tamariscifolia extract 0.015 Glycerol 5.75 Gluconolactone 7 Lauroyl Lysine 4 Propanediol 2 1,2-Hexanediol 0.8 Bisabolol 0.5 Sodium citrate 1.2 Schisandra Sphenanthera Fruit Extract 0.25 Cellulose 3 Squalane 2.5 Dicaprylyl Carbonate 2.5 3-O-Ethyl Ascorbic Acid 2 Disodium Cetearyl Sulfosuccinate 0.5 Polyacrylate Crosspolymer-6 0.5 Helianthus Annuus (Sunflower) Seed Oil 0.03 Xanthan Gum 0.35 Preservatives Qs Water Qsp 100

[0114] [Tableaux3] Ingredients A3 Niacinamide 2 Cystoseira Tamariscifolia extract 0.015 Glycerol 8.35 Gluconolactone 7 Lauroyl Lysine 2 Caprylic / Capric Triglyceride 7 Coco-Caprylate / Caprate 6 Hydrogenated Vegetable Glycerides 2 Propanediol 4 1,2-Hexanediol 1 Behenyl alcohol 1 Propylene glycol 0.5 Disodium Cetearyl Sulfosuccinate 1 Polyacrylate Crosspolymer-6 0.6 Xanthan gum 0.3 Preservatives Qs Water Qsp 100

[0115] [Tables4] Ingredients: A4 Niacinamide 2 Cystoseira Tamariscifolia extract 0.015 Glycerol 5.75 Lauroyl Lysine 2 Dicaprylyl Carbonate 15 Cetearyl Alcohol 2.5 Pentaerythrityl Distearate 2.5 Dibutyl Adipate 2 Helianthus Annuus (Sunflower) Seed Oil 0.03 Silica 2 Citric Acid 0.03 Carnosine 0.2%, Pentylene Glycol 0.8%, Bisabolol 0.5%, Disodium Cetearyl Sulfosuccinate 2%, Coco-Glucoside 0.15%, Disodium Lauryl Sulfosuccinate 0.04%, Acrylates / CI 222 Copolymer, Alkyl Methacrylate 1.4%, Ammonium Acryloyldimethyltaurate / VP Copolymer 0.4%, Arginine 0.2%, UVA and / or UVB Filters 20.25%, Biosaccharide Gum-1 0.03%, Xanthan Gum 0.2%, Preservatives Qs, Water Qsp 100%

[0116] [Tables5] Ingredients: A5 Niacinamide 2 Cystoseira Tamariscifolia extract 0.010 Glycerol 10.5 Acetyl Glucosamine 1 Octadecenedioic Acid 4 Caprylic / Capric Triglyceride 7 Dicaprylyl Carbonate 6 Isopropyl Isostearate 2 Glyceryl Stearate 1 Sorbitan Stearate 1 Glyceryl Caprylate 0.5 Beeswax (Cera Alba) 0.5 Cetearyl Ethylhexanoate 2 PEG-100 Stearate 1 Polysorbate 60 0.8 Carbomer 0.14 UVA and / or UVB filters 6.5 Xanthan gum 0.25 Preservatives Qs Water Qsp 100

[0117] It has been observed that compositions Al to A5 make it possible to prevent and treat effectively the appearance of hyperpigmentation of the skin and hair.

[0118] Compositions Al to A5 are also particularly effective for whitening the skin, brightening the complexion and evening out the complexion.

[0119] Example 2: Clinical dermatological studies were conducted by a dermatologist for compositions A3, A4 and A5 of example 1.

[0120] The dermatological clinical study of composition A3 was carried out on 35 female volunteers with an average age of 51 years: 11 from Poland (phototype I to III, light skin), 12 from China (phototype III to IV) and 12 from Mauritius (phototype V to VI, dark skin).

[0121] The dermatological clinical study of composition A4 was carried out on 46 female volunteers with an average age of 51 years: 12 from Poland (phototype I to III), 11 from Tunisia (phototype IV), 12 from China (phototype III to IV) and 11 from Mauritius (phototype V to VI).

[0122] The dermatological clinical study of composition A5 was carried out on 47 female volunteers with an average age of 54 years: 13 from Poland (phototype I to III), 12 from Tunisia (phototype IV), 12 from China (phototype III to IV) and 10 from Mauritius (phototype V to VI).

[0123] For the evaluation of composition A3, each volunteer applies between 0.5 and 2g of composition to their face, in the evening before going to bed, from J0 to J55.

[0124] For the evaluation of composition A4, each volunteer applies between 1 and 2g of composition to their face, in the morning from J0 to J55.

[0125] For the evaluation of composition A5, each volunteer applies between 8 and 10g of composition to their body, twice a day, in the morning and in the evening before going to bed, from J0 to J55.

[0126] The dermatologist in charge of the study performed a visual scoring of the skin condition of each volunteer's body at the start of the study (D0), 28 days after the start (D28) and 56 days after the start (D56), on structured scales.

[0127] Evaluation of the density of pigmentation alterations, number of spots, spot size and spot / normal skin contrast:

[0128] Density of pigmentation disorders: a global assessment of the severity of pigmentary alterations in terms of number, contrast, and surface area is performed. The dermatologist assesses the density of the spots, the number of spots per unit area, according to the grades defined from 0 to 7 scores (Atlas volume 2, Asian type - Skin aging atlas - Pages 80-81).

[0129] For volunteers with phototype V to VI, the dermatologist assesses the density of the spots, according to the grades defined from 0 to 6 (Atlas volume 3, African American Population - Atlas of skin aging - Page 72-73).

[0130] The lower the score, the lower the density of pigmentary alterations and the better the homogeneity of skin pigmentation.

[0131] Number of spots: this is an assessment by the dermatologist of the number of spots on a unit area, according to the grades defined from 0 to 5 scores (Atlas volume 2, Asian type - Atlas of skin aging - Page 85-86).

[0132] The lower the score, the lower the number of tasks and the better the depigmenting action.

[0133] Spot size: This is an assessment by the dermatologist of the size of an isolated spot, according to the grades defined from 0 to 7 (Atlas volume 2, Asian type- Atlas of skin aging- Page 92-93).

[0134] The lower the score, the smaller the task and the better the depigmenting action.

[0135] Spot / normal skin contrast: This consists of an evaluation of the contrast between a spot and its immediate environment. The dermatologist assesses the contrast of the spot, without taking into account the size of the spot, according to the grades defined from 0 to 7 (Atlas volume 2, Asian Type - Atlas of Skin Aging - Page 88-89).

[0136] The lower the score, the lower the contrast in pigmentation between the spot and normal skin and the better the depigmenting action.

[0137] Results: The results of the assessments of compositions A3, A4 and A5 are grouped in the tables below.

[0138] A3 / Phototypes I to IV:

[0139] [Tableauxô] A3 Day 0 Average ± SE M Day 28 Average ± SE MA% of average Phototypes I to IV Density of pigmentary alterations 3.6 + 0.2 3.3 + 0.2 -9% Number of spots 3.2 + 0.2 2.9 + 0.2 -9% Spot size 2.6 + 0.2 2.5 + 0.2 -5% Spot / normal skin contrast 3.1 + 0.1 2.9 + 0.1 -6%

[0140] [Tables?] A3 Day 0 Average + SE M Day 56 Average + SE MA% of average Phototypes I to IV Density of pigment alterations 3.6 + 0.2 3.0 + 0.2 - 16% Number of spots 3.2 + 0.2 2.6 + 0.2 - 18% Spot size 2.6 + 0.2 2.2 + 0.2 - 17% Spot / normal skin contrast 3.1 + 0.1 2.6 + 0.2 - 16%

[0141] For phototype I to IV panels, after 28 and 56 days of use, it was observed that composition A3 according to the invention induced a significant decrease in the density of pigmentary disorders, the number, size and contrast of brown spots on average.

[0142] A3 / Phototypes V to VI:

[0143] [Tables8] A3 Day 0 Average + SE M Day 28 Average + SE MA% of average Phototypes V to VI Density of pigment alterations 3.2 + 0.3 2.8 + 0.3 - 12% Number of spots 3.0 + 0.3 2.7 + 0.3 - 11% Spot size 3.3 + 0.2 2.8 + 0.3 - 17% Spot / normal skin contrast 3.0 + 0.2 2.3 + 0.2 -22%

[0144] [Tables9] A3 Day 0 Mean ± SE M Day 56 Mean ± SE MA% of mean Phototypes V to VI Density of pigment alterations 3.2 + 0.3 2.4 + 0.3 -25% Number of spots 3.0 + 0.3 2.1 + 0.3 -31% Spot size 3.3 + 0.2 2.3 + 0.3 -30% Spot / normal skin contrast 3.0 + 0.2 1.7 + 0.2 -43%

[0145] For phototype V to VI panels, after 28 and 56 days of use, it was observed that composition A3 according to the invention induced a significant decrease in the density of pigmentation disorders, the number, the size of brown spots and the contrast between spots and normal skin, on average.

[0146] It is concluded that composition A3 according to the invention significantly improves the homogeneity of skin pigmentation and the pigmentary contrast between brown spots and normal skin. Furthermore, composition A3 according to the invention also provides an anti-spot effect (depigmenting action).

[0147] A4 / Phototypes I to IV:

[0148] [TableauxlO] A4 Day 0 Average + SE M Day 28 Average + SE MA% of average Phototypes I to IV Density of pigment alterations 3.9 + 0.2 3.6 + 0.2 -7% Number of spots 3.1 + 0.2 3.0 + 0.2 -4% Spot size 2.6 + 0.2 2.5 + 0.2 -7% Spot / normal skin contrast 3.1 + 0.1 2.8 + 0.1 -7%

[0149] [Tableauxll] A4 J0 J56 A% on the average Mean ± SE M Mean + SE M Phototypes I to IV Density of pigmentary alterations 3.9 + 0.2 3.1 + 0.2 - 19% Number of spots 3.1 + 0.2 2.8 + 0.2 - 11% Spot size 2.6 + 0.2 2.2 + 0.1 - 16% Spot / normal skin contrast 3.1 + 0.1 2.4 + 0.2 - 21%

[0150] For phototype I to IV panels, after 28 and 56 days of use, it was observed that composition A4 according to the invention induced a significant decrease in the density of pigmentary disorders, the number, the size of brown spots and the contrast between spots and normal skin, on average.

[0151] A4 / Phototypes V to VI:

[0152] [Tables 12] A4 Day 0 Average + SE M Day 28 Average + SE MA% of average Phototypes V to VI Density of pigment alterations 4.4 + 0.3 3.8 + 0.3 - 12% Number of spots 4.0 + 0.2 3.5 + 0.3 - 12% Spot size 4.6 + 0.4 4.1 + 0.5 - 11% Spot / normal skin contrast 3.4 + 0.3 2.8 + 0.3 - 16%

[0153] [Tables 13] A4 Day 0 Average + SE M Day 56 Average + SE MA% of average Phototypes V to VI Density of pigment alterations 4.4 + 0.3 3.3 + 0.3 -24% Number of spots 4.0 + 0.2 3.0 + 0.3 -24% Spot size 4.6 + 0.4 3.2 + 0.4 -29% Contrast between blemish and normal skin: 3.4 + 0.3, 2.5 + 0.4, -25%

[0154] For phototype V to VI panels, after 28 and 56 days of use, it was observed that composition A4 according to the invention induced a significant decrease in the density of pigmentary disorders, the number, the size of brown spots and the contrast between spots and normal skin, on average.

[0155] It is concluded that composition A4 according to the invention significantly improves the homogeneity of skin pigmentation and the pigmentary contrast between brown spots and normal skin. Furthermore, composition A4 according to the invention also provides an anti-spot effect (depigmenting action).

[0156] A5 / Phototypes I to IV:

[0157] [Tables 14] A5 Day 0 Mean ± SE M Day 28 Mean ± SE MA% of mean Phototypes I to IV Density of pigment alterations 2.9 + 0.3 2.6 + 0.2 - 11% Number of spots 2.4 + 0.2 2.2 + 0.2 - 12% Spot size 2.2 + 0.2 2.1 + 0.2 -6% Spot / normal skin contrast 2.9 + 0.1 2.4 + 0.1 - 17%

[0158] [Tables 15] A5 Day 0 Average + SE M Day 56 Average + SE MA% of average Phototypes I to IV Density of pigment alterations 2.9 + 0.3 2.4 + 0.2 - 18% Number of spots 2.4 + 0.2 2.0 + 0.2 - 19% Spot size 2.2 + 0.2 1.8 + 0.2 - 18% Spot / normal skin contrast 2.9 + 0.1 2.1 + 0.1 - 27%

[0159] For phototype I to IV panels, after 28 and 56 days of use, it was observed that composition A5 according to the invention induced a significant decrease in the density of pigmentary disorders, the number, the size of brown spots and the contrast between spots and normal skin, on average.

[0160] A5 / Phototypes V to VI:

[0161] [Tables 16] A5 Day 0 Mean ± SE M Day 28 Mean ± SE MA% of mean Phototypes V to VI Density of pigment alterations 2.3 + 0.3 2.1 + 0.3 -9% Number of spots 2.4 + 0.3 2.1 + 0.3 -11% Spot size 2.8 + 0.5 2.6 + 0.5 -8% Spot / normal skin contrast 2.8 + 0.2 2.2 + 0.3 -23%

[0162] [Tables 17] A5 Day 0 Average + SE M Day 56 Average + SE MA% of average Phototypes V to VI Density of pigment alterations 2.3 + 0.3 1.5 + 0.4 -36% Number of spots 2.4 + 0.3 1.4 + 0.3 -40% Spot size 2.8 + 0.5 2.0 + 0.5 -28% Spot / normal skin contrast 2.8 + 0.2 1.3 + 0.3 -53%

[0163] For phototype V to VI panels, after 28 and 56 days of use, it was observed that composition A5 according to the invention induced a significant decrease in the density of pigmentation disorders, the number, the size of brown spots and the contrast between spots and normal skin, on average.

[0164] It is concluded that composition A5 according to the invention significantly improves the homogeneity of skin pigmentation and the pigmentary contrast between brown spots and normal skin. Furthermore, composition A5 according to the invention also provides an anti-spot effect (depigmenting action).

[0165]

[0166]

[0167]

[0168]

[0169]

[0170]

[0171]

[0172]

[0173]

[0174] Skin color assessment The colorimetric measurement of the skin is carried out using a CM700-d Spectrophotometer® (Minolta') equipped with an 8 mm diameter head. The Spectrophotometer® converts colors within the range of human perception into a digital code composed of three parameters: L* : represents lightness (from dark to pale) a* : represents the range of greens to reds b* : represents the range of blues to yellows, a* and b* are chrominance parameters; L* is a luminance parameter. After calibration, measurements are taken directly on the skin using a pulsed Xenon light source and a dual-beam system to measure the emitted light and correct any slight deviation. In the assessment of skin pigmentation, the parameters L* (lightness characteristic) and b* (melanosis characteristic) are studied. These two parameters are used to calculate the "Individual Typological Angle" (ITA°), which defines the degree of skin pigmentation of a person by integrating lightness (L*) and the melanization parameter (b*), according to the following formula: ITA° = [Arc tan((L*-50) / b*)] x 180 / n The higher the Individual Typological Angle (ITA°), the lighter the skin. The Eab* parameter is also calculated. It takes into account overall variations in hue and brightness. The difference between the pigmented area (spot) and the surrounding "normal" skin is calculated using the following formulas: AEab* = (Aa*2 + Ab*2 + AL*2)1 / 2 ^AEab* [AEabM pigmented zone] - [AEab' normal skin] When the AAEab* is negative, it indicates that the pigmentation of the pigmented area is approaching that of normal skin pigmentation and is becoming lighter. Conversely, when the AAEab* is positive, it indicates that the pigmentation of the pigmented area is moving away from that of normal skin pigmentation and is becoming darker. The lower the AAEab* (i.e., negative), the lower the contrast in pigmentation between the pigmented area and normal skin, and the better the depigmenting action. Results : The results obtained across all cumulative panels (phototypes I to VI) are grouped in the tables below. [Tables 18] Composition A3 Kinetic Zones A (average) A% of the average L* A J28 Pigmented +0.9 + 2% Normal skin +0.7 + 1% Pigmented / Normal skin +0.3 + 1% A J56 Pigmented +1.4 + 3% Normal skin +1.1 + 2% Pigmented / Normal skin +0.3 + 1% a* A J28 Pigmented -0.2 -2% Normal skin -0.3 -3% Pigmented / Normal skin +0.1 + 1% A J56 Pigmented -0.2 -2% Normal skin -0.2 -2% Pigmented / Normal skin -0.1 - 1% b* A J28 Pigmented +0.1 0% Normal skin -0.5 -3% Pigmented / Normal skin +0.6 + 3% A J56 Pigmented -0.2 - 1% Normal skin -0.4 -3% Pigmented / Normal skin +0.3 + 2% ITA° A J28 Pigmented +3 - Normal skin +2 - Pigmented / Normal skin +1 - A J56 Pigmented +5 - Normal skin +4 - Pigmented / Normal skin +1 - AaEsù* A J28 Pigmented - - Normal skin - - Pigmented / Normal skin -0.5 -11% A J56 Pigmented - - Normal skin - - Pigmented / Normal skin -0.6 -12%

[0175] [Tables 19] Composition A4 Kinetic Zones A (average) A% of average L* A Day 28 Pigmented +1.6 + 4% Normal skin +0.1 + 1% Pigmented / Normal skin +1.5 + 3% A Day 56 Pigmented +2.5 + 5% Normal skin +0.7 + 1% Pigmented / Normal skin +1.8 + 4% a* A Day 28 Pigmented -0.7 -6% Normal skin +0.2 + 1% Pigmented / Normal skin -0.9 - 8% A Day 56 Pigmented -0.5 -4% Normal skin +0.2 + 2% Pigmented / Normal skin -0.6 -6% b* A Day 28 Pigmented -0.3 -2% Normal skin -0.4 -2% Pigmented / Normal skin 0 + 1% A Day 56 Pigmented -0.3 -2% Normal skin -0.4 -2% Pigmented / Normal Skin +0.1 + 1% ITA° A J28 Pigmented +5 - Normal Skin +1 - Pigmented / Normal Skin +4 - A J56 Pigmented +8 - Normal Skin +3 - Pigmented / Normal Skin +5 - ^AEab* A J28 Pigmented - - Normal Skin - - Pigmented / Normal Skin -1.2 - 17% At J56 Pigmented - - Normal Skin - - Pigmented / Normal Skin -1.6 -24%

[0176] After 28 and 56 days of use, it was observed that the compositions A3 and A4 according to the invention induced a significant increase in the parameters L* and ITA° on average, reflecting an increase in skin clarity and a reduction in skin pigmentation.

[0177] We also observe a decrease in the AAEab* parameter, reflecting a reduction in the differences in pigmentation between "normal" skin and brown spots.

[0178] Evaluation of skin tone radiance / luminosity The measurement is performed using a VISIA® skin analysis imaging system from CANFIELD® imaging systems.

[0179] The VISIA® allows you to take photos with different types of lighting and very fast image capture.

[0180] Repositioning control is carried out directly on the computer screen by means of an overlay visualization of the images at each acquisition time.

[0181] Skin tone scoring is performed on photographs by a trained expert who evaluates the following parameters on an unstructured scale: corresponding to a scale from 0 (dull) to 10 (radiant / bright).

[0182] The higher the score, the more radiant and luminous the complexion.

[0183] Results: The results obtained across all cumulative panels (phototypes I to VI) are grouped in the table below.

[0184] [Tables20] Composition A4 Day 0 (Average ± SEM) Day 1 (Average ± SEM) A% of average Complexion radiance / luminosity 4.5 ± 0.2 Day 28 4.8 ± 0.2 + 6% Day 56 4.9 ± 0.2 + 8%

[0185] After 56 days of use, it was observed that composition A4 according to the invention induced a significant improvement in the radiance of the complexion (the skin is more radiant and the complexion brighter) of +8% on average (effect observed in 87% of subjects).

Claims

Demands

1. Composition comprising: i. at least one first active ingredient selected from niacinamide, isoniacinamide, methyl niacinamide chloride, niacinamide salts and isoniacinamide salts, the total content of which is in the range of 2 to 4% by weight, relative to the total weight of the composition; and ii. at least one second active ingredient selected from extracts of algae of the genus Cystoseira, the total content of which is in the range of 0.01 to 0.02% by weight, relative to the total weight of the composition.

2. Composition according to the preceding claim, characterized in that the first active ingredient(s) are selected from niacinamide, risoniacinamide, methyl niacinamide chloride, niacinamide ascorbate, niacinamide glycolate, niacinamide hydroxybenzoate, niacinamide hydroxycitrate, niacinamide lactate, niacinamide malate, niacinamide mandelate, niacinamide salicylate, niacinamide thioctate, and mixtures thereof; preferably from niacinamide, niacinamide ascorbate, niacinamide glycolate, niacinamide hydroxybenzoate, niacinamide hydroxycitrate, niacinamide lactate, niacinamide malate, niacinamide mandelate, niacinamide salicylate, niacinamide thioctate, and mixtures thereof; more preferably the first active ingredient is niacinamide.

3. Composition according to any one of the preceding claims, characterized in that the second active ingredient(s) are selected from Cystoseira Amentacea extract, Cystoseira Caespitosa extract, Cystoseira Branchycarpa extract, Cystoseira Baccata extract, Cystoseira Balearica extract, Cystoseira Compressa extract, Cystoseira Humilis extract, Cystoseira Tamariscifolia extract, and mixtures thereof; preferably the second active ingredient is an extract of Cystoseira Tamariscifolia.

4. A composition according to any one of the preceding claims, characterized in that the weight ratio of the total content of the first active ingredient(s) to the total content of the second active ingredient(s) is greater than or equal to 1; preferably greater than 1; more preferably between 5 and 1,000; more preferably between 10 and 800; better between 50 and 500; better still between 100 and 450; or even between 120 and 400; or even between 130 and 270.

5. A composition according to any one of the preceding claims, characterized in that it further comprises one or more C2-C8 polyols; preferably selected from C3-C6 polyols, ethylene glycol, and mixtures thereof; more preferably from propylene glycol, 1,3-propanediol, 1,3-butylene glycol, pentane-1,2-diol, dipropylene glycol, hexylene glycol, pentylene glycol, glycerol, ethylene glycol, and mixtures thereof; more preferably still the composition comprises glycerol.

6. A composition according to any one of the preceding claims, characterized in that it further comprises one or more beneficial agents selected from gluconolactone, acetyl glucosamine, lauroyl lysine, octadecenedioic acid and its salts, Bacillus ferments, bisabolol, 3-o-ethyl-ascorbic acid and its salts, citric acid and its salts, Schisandra sphenanthera fruit extract, and mixtures thereof; more preferably from gluconolactone, acetyl glucosamine, Schisandra sphenanthera fruit extract, and mixtures thereof; more preferably still from gluconolactone, acetyl glucosamine, and mixtures thereof.

7. Composition according to any one of the preceding claims, characterized in that it is selected from compositions A1, A2, A3, A4 and A5 respectively prepared from the ingredients indicated in Tables 1, 2, 3, 4 and 5.

8. Composition according to any one of the preceding claims, characterized in that it is selected from compositions A3, A4 and A5 respectively prepared from the ingredients indicated in Tables 3, 4 and 5.

9. Use of the composition according to any one of the preceding claims, to prevent and / or treat the appearance of hyperpigmentation of the skin and / or hair.

10. Use of the composition according to any one of the preceding claims, to whiten the skin and / or lighten the complexion, and / or even out the complexion.